Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma

ClinicalTrials.gov Show glossary Search for terms Hide glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.

Related documents

• Glioblastoma in adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions.#450043
• Safety and Preliminary Efficacy of a Metabolically Armed Chimeric Antigen Receptor T Cell Therapy Targeting EGFRvIII for Recurrent Glioblastoma#1044894
• Glioblastoma: epidemiology, molecular pathogenesis, diagnosis, management, and therapeutic resistance.#170593
• In Situ Immune Parameters and Their Prognostic Role on the Survival of Patients With Glioblastoma#861861
• Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme#633736